Pediatric allergy medications: Review of currently available formulations

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 2069-2079

  Scadding, Glenis ^a  

^a ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

Author keywords

Allergic rhinitis; Antihistamines; Liquid oral medications; Orodispersible tablets; Parental preferences; Pediatric medications; Syrups

Indexed keywords

ACESULFAME; ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; ANTITUSSIVE AGENT; ASPARTAME; AZELASTINE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EXPECTORANT AGENT; FEXOFENADINE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HYDROXYZINE; IPRATROPIUM BROMIDE; LEVOCETIRIZINE; LORATADINE; METHAMPHETAMINE; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL; PHENYLEPHRINE; PSEUDOEPHEDRINE; SUCRALOSE; SWEETENING AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; ALLERGIC RHINITIS; BLOATING; CHILD; CLINICAL TRIAL; CONVULSION; DENTAL CARIES; DEPRESSION; DIARRHEA; DISPERSIBLE TABLET; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY NOSE; EPISTAXIS; EUROPE; GASTROINTESTINAL DISEASE; HALLUCINATION; HAY FEVER; HEADACHE; HEALTH CARE PERSONNEL; HEART RATE; HUMAN; LIVER CONGESTION; MENTAL DISEASE; NAUSEA; NONHUMAN; PANIC; PERENNIAL RHINITIS; PHYSICIAN; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; RHINORRHEA; SIDE EFFECT; SNEEZING; TABLET FORMULATION; UNCONSCIOUSNESS; UNITED STATES; XEROSIS;

ANTI-ALLERGIC AGENTS; DOSAGE FORMS; DRUG EVALUATION; HUMANS; PEDIATRICS; RHINITIS, ALLERGIC, SEASONAL;

EID: 67651002562     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903116875     Document Type: Review

References (137)

1. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43
2. Bousquet J, Ansotegui IJ, van Ree R, et al. European Union meets the challenge of the growing importance of allergy and asthma in Europe. Allergy 2004;59:1-4
3. Bousquet J, Ndiaye M, Ait-Khaled N, et al. Management of chronic respiratory and allergic diseases in developing countries. Focus on sub-Saharan Africa. Allergy 2003;58:265-83
4. 2LEN and AllerGen) Allergy 2008;63(Suppl. 86):8-160
5. Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007;120:381-7
6. Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004;26:1876-89
7. Vuurman EF, van Veggle LM, Ulterwijk MM, et al. Seasonal AR and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6
8. Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549-58
9. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
10. Baena-Cagnani CE, Berger WE, Dubuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003;130:307-13
11. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485-91
12. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:19-42
13. 2LEN). Allergy 2006;61:1086-96
14. Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58-70
15. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116-34
16. Dykewicz MS, Fineman S. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518
17. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am 2005;25:283-99
18. Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 2004;27:883-98
19. McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs 1998;56:91-114
20. Cutler DL, Banfield C, Melton B, et al. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006;19:146-53
21. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial AR after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:e22
22. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with AR. Ann Allergy Asthma Immunol 2003;90:56-62
23. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal AR. J Allergy Clin Immunol 1999;104:107-14
24. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997;19:1330-9
25. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal AR. Pediatrics 1993;92:594-9
26. Zuberbier T, Maurer M, Augustin M. Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy 2008;63:1560-1
27. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007;99:69-76
28. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071-7
29. Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317-26
30. Transgrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 2002;22:1458-67
31. Mahr TA, Sheth KK, Boyle JM. Lack of efficacy and bothersome side effects decrease treatment adherence in children with allergic rhinitis. Presented at the American College of Allergy, Asthma and Immunology Annual Meeting; Dallas, TX; Nov 9-14, 2007
32. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? Biodrugs 2001;15:453-63
33. Meltzer EO. Treatment options for the child with allergic rhinitis. Clin Pediatr (Phila) 1998;37:1-10
34. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med 2005;4:21-9
35. Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev 2007;Jan 24;(1):CD001953
36. Food and Drug Administration. FDA releases recommendations regarding use of over-the-counter cough and cold products: products should not be used in children under 2 years of age; evaluation continues in older populations [FDA news release]. Rockville, MD: Center for Drug Evaluation and Research, January 17, 2008. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2008/ucm116839.htm [Last accessed 3 June 2009]
37. Statement from CHPA on the voluntary label updates to oral OTC children's cough and cold medicines [press release]. Washington, DC: Consumer Healthcare Products Association, October 7, 2008. Available at: http://www.chpa-info.org/ 10-07-08-PedCC.aspx [Last accessed 3 June 2009]
38. Legal requirements for the sale and purchase of drug products containing pseudoephedrine, ephedrine, and phenylpropanolamine [press release]. Washington, DC: US Food and Drug Administration, May 8, 2006. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm072423.htm [Last accessed 3 June 2009]
39. Nasal decongestants get new sales restrictions [press release]. London, England: Medicines and Healthcare products Regulatory Agency, August 29, 2007. Available at: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2032216 [Last accessed 3 June 2009]
40. Pseudoephedrine rescheduling - information for sponsors. Canberra, Australia: Australian Government Department of Health and Ageing Administration Therapeutic Goods Agency, September 15, 2008. Available at: http://www.health. gov.au/internet/main/publishing.nsf/Content/annual-report2007.htm [Last accessed 3 June 2009]
41. Eccles R. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse. Br J Clin Pharmacol 2007;63:10-14
42. Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. Eur J Clin Pharmacol 1982;21:335-41
43. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993;13(pt 2):116S-28S
44. Atrovent Nasal Spray [prescribing information]. Ridgefield, CT: Boehringer Ingleheim Pharmaceuticals, Inc, 2003. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2003/020394s005lbl.pdf [Last accessed 3 June 2009]
45. Wagenmann M, Naclerio RM. Complications of sinusitis. J Allergy Clin Immunol 1992;90(pt 2):552-4
46. Mygind N, Borum P. Intranasal ipratropium: literature abstracts and comments. Rhinol Suppl 1989;9:37-44
47. Borum P, Mygind N, Schultz Larsen F. Intranasal ipratropium: a new treatment for perennial rhinitis. Clin Otolaryngol Allied Sci 1979;4:407-11
48. Galant SP, Wilkinson R. Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? BioDrugs 2001;15:453-63
49. Meltzer EO, Orgel HA, Biondi R, et al. Ipratropium nasal spray in children with perennial rhinitis. Ann Allergy Asthma Immunol 1997;78:485-91
50. James IGV, Campbell LM, Harrison JM, et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003;19:313-20
51. Meltzer EO, NasalCrom Study Group. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther 2002;24:942-52
52. Vermeulen J, Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol 1994;5:209-13
53. Meltzer EO. Allergic rhinitis: managing the pediatric spectrum. Allergy Asthma Proc 2006;27:2-8
54. Blaiss MS, Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004;20:1937-52
55. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004;5:679-86
56. Nathan RA. Do leukotriene receptor antagonists have a place in pharmacotherapy of allergic rhinitis? Ann Allergy Asthma Immunol 2003;90:466-8
57. van Adelsberg J, Philip G, LaForce CF et al., for the Montelukast Spring Rhinitis Investigator Group. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22
58. van Adelsberg J, Philip G, Pedinoff AJ et al., for the Montelukast Fall Rhinitis Study Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76
59. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600
60. Philip G, Malmstrom K, Hampel FC et al., for the Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8
61. Kurowski M, Kuna P, Górski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004;59:280-8
62. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-22
63. Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004;92:367-73
64. Borres MP, Bråkenhielm G, Irander K. How many teenagers think they have allergic rhinoconjunctivitis and what they do about it. Ann Allergy Asthma Immunol 1997;78:29-34
65. Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol 2004;93:345-50
66. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2004;131:225-31
67. American Academy of Pediatrics Committee on Drugs. 'Inactive' ingredients in pharmaceutical products: update (subject review). Pediatrics 1997;99:268-78
68. Bogner RH, Wilkosz MF. Fast-dissolving tablets. US Pharmacist, 2002. Available at: http://www.uspharmacist.com/oldformat.asp?url=newlook/files/feat/ fastdissovling.htm [Last accessed 24 April 2009]
69. Reig AR, Fernandez MJP, Cervera JG, et al. Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectances. Allergol et Immunopathol 2006;34:107-12
70. Fineman SM. Clinical experience with azelastine nasal spray in children: physician survey of case reports. Pediatr Asthma Allergy Immunol 2001;15:49-54
71. Roberts KR, Linder L, Sund ML. Glucose incorporation by human dental plaque bacteria. Caries Res 1981;15:492-500
72. Olmez S, Uzamis M, Erdem G. Association between early childhood caries and clinical, microbiological, oral hygiene and dietary variables in rural Turkish children. Turk J Pediatr 2003;45:231-6
73. Durward C, Thou T. Dental caries and sugar-containing liquid medicines for children in New Zealand. New Zealand Dental Journal 1997;93:124-9
74. Maguire A, Rugg-Gunn AJ, Butler TJ. Dental health of children taking antimicrobial and non-antimicrobial liquid oral medication long-term. Caries Res 1996;30:16-21
75. Shaw L, Glenwright HD. The role of medications in dental caries formation: need for sugar-free medication for children. Pediatrician 1989;16:153-5
76. European Commission. Guidelines, Volume 3B - Medicinal Products for Human Use. Excipients in the label and package leaflet of medicinal products for human use, July 2003
77. Aerius Summary of Product Characteristics. Brussels, Belgium: SP Europe, 2007. Available at: http://www.emea.europa. eu/humandocs/PDFs/EPAR/aerius/H-313- PI-en.pdf [Last accessed 3 June 2009]
78. Allegra® (fexofenadine hydrochloride) prescribing information. sanofi-aventis U.S. LLC, Bridgewater, NJ, USA, 2007. Available at: http://products.sanofi-aventis.us/allegra/allegra.html [Last accessed 3 June 2009]
79. Neoclarityn Summary of Product Characteristics. Brussels, Belgium: SP Europe, January 2008. Available at: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/neoclarityn/H-314-PI-en.pdf [Last accessed 3 June 2009]
80. Xyzal® (levocetirizine dihydrochloride) 0.5 mg/ml oral solution. UCB Pharma Ltd., Slough, UK, January 2008. Available at: http://emc.medicines.org. uk/emc/assets/c/html/DisplayDoc.asp?format=original&documentid=19876 [Last accessed 3 June 2009]
81. Benadryl. Available at: www.benadrylusa.com [Last accessed 3 June 2009]
82. Children's Claritin Fruit Flavored Syrup. Available at: http://www.claritin.com/pdf/readthebox/claritin-child-fruit.pdf [Last accessed 3 June 2009]
83. Children's Claritin Grape Flavored Syrup. Available at: http://www.claritin.com/pdf/readthebox/claritin-child-grape.pdf [Last accessed 3 June 2009]
84. Dimetapp Children's Cold and Allergy Elixir. Available at: http://www.dimetapp.com/cold/rsn-caelixir.asp [Last accessed 3 June 2009]
85. Piriteze Allergy Syrup. Available at: http://www.piriton. co.uk/Piriteze-Allergy-Syrup.htm [Last accessed 3 June 2009]
86. Piriton Syrup. Available at: http://www.piriton.co.uk/Piriton-Syrup.htm [Last accessed 3 June 2009]
87. Triaminic Cold and Allergy Liquid. Available at: http://www.triaminic. com/us-en/products/20604CR-ingredients. shtml [Last accessed 3 June 2009]
88. Tylenol Children's Cold & Allergy Plus Oral Suspension. Available at: http://www.tylenol.com/product-detail.jhtml?id=tylenol/children/prod-cca. inc&prod=subpcca# [Last accessed 3 June 2009]
89. Tylenol Children's Cough and Runny Nose Plus Oral Suspension. Available at: http://www.tylenol.com/product-detail.jhtml?id=tylenol/children/prod- coughrunnose.inc&prod=child-coughrunnose# [Last accessed 3 June 2009]
90. Children's Zyrtec Allergy Syrup. Available at: http://www.zyrtec.com/ econsumer/zyrtec/product.view?body=/zyrtec/pages/prod-children.jsp&s= prod-children&p&t [Last accessed 3 June 2009]
91. Peres KG, Oliveira CT, Peres MA et al. Sugar content in liquid oral medicines for children. Rev Saúde Pública 2005;39:486-9
92. Mackie IC, Bentley E. Sugar-containing or sugar-free paediatric medicines: does it really matter? Dent Update 1994;21:192-4
93. Department of Health, Report on Health & Social Subjects No 37 Dietary Sugars and Human Disease. Report of the Panel on Dietary Sugars, Committee on Medical Aspects of Food Policy. London: HMSO, 1989
94. American Dental Association Position Statement. Role of sugar-free foods and medications in maintaining good oral health. November 1, 1999. Available at: http://www.ada.org/prof/resources/positions/statements/sugarfre.asp [Last accessed 3 June 2009]
95. Scottish Intercollegiate Guidelines Network. Section 5.4: Sugar-free medicines. In: Targeted Prevention of Dental Caries in the Permanent Teeth of 6-16 Year Olds Presenting for Dental Care. Edinburgh, Scotland: SIGN, 2000. Available at: http://www.sign.ac.uk/pdf/sign47.pdf [Last accessed 3 June 2009]
96. Grabitske HA, Slavin JL. Gastrointestinal effects of low-digestible carbohydrates. Crit Rev Food Sci Nut 2009;49:327-60
97. Oku T, Nakamura S. Threshold for transitory diarrhea induced by ingestion of xylitol and lactitol in young male and female adults. J Nutr Sci Vitaminol (Tokyo) 2007;53:13-20
98. Storey D, Lee A, Bornet F, et al. Gastrointestinal tolerance of erythritol and xylitol ingested in a liquid. Eur J Clin Nutr 2007;61:349-54
99. Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled, artificial food colorings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child 2004;89:506-11
100. Artificial sweeteners: no calories. . .sweet! FDA Consumer Magazine July/August 2006. Available at: http://www.fda.gov/fdac/features/2006/406- sweeteners.html [Last accessed 3 June 2009]
101. Koppel BS, Harden CL, Daras M. Tegretol excipient-induced allergy. Arch Neurol 1991;48:789
102. Weber RW, Hoffman M, Raine Jr DA, et al. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-7
103. Chafee FH, Settipane GA. Asthma caused by FD&C approved dyes. J Allergy 1967;40:65-72
104. Larsen WG. Cosmetic dermatitis due to a dye (D&C Yellow #11). Contact Dermatitis 1975;1:61
105. Castelain PY, Piriou A. Photosensitization eczema with positive erythrosine test. Contact Dermatitis 1978;4:305
106. Fisherman EW, Cohen GN. Aspirin and other cross-reacting small chemicals in known aspirin intolerant patients. Ann Allergy 1973;31:476-84
107. Mancuso G, Staffa M, Errani A, et al. Occupational dermatitis in animal feed mill workers. Contact Dermatitis 1990;22:37-41
108. Supramaniam G, Warner JO. Artificial food additive intolerance in patients with angio-oedema and urticaria. Lancet 1986;2:907-9
109. Michaelsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. Br J Dermatol 1973;88:525-32
110. Michaelsson G, Pettersson L, Juhlin L. Purpura caused by food and drug additives. Arch Dermatol 1974;109:49-52
111. Bell T. Colourants and drug reactions. Lancet 1991;338:55-6
112. Gross PA, Lance K, Whitlock RJ, et al. Additive allergy: allergic gastroenteritis due to Yellow Dye #6. Ann Intern Med 1989;111:87-8
113. Jenkins P, Michaelsson R, Emerson PA. Adverse drug reaction to sunset-yellow in rifampicin isoniazid tablet. Lancet 1982;2:385
114. Desmond RE, Trautlein JJ. Tartrazine (FD&C Yellow #5) anaphylaxis: a case report. Ann Allergy 1981;46:81-2
115. Trautlein JJ, Mann WJ. Anaphylactic shock caused by yellow dye (FD&C No 5 and FD&C No 6) in an enema (case report). Ann Allergy 1978;41:28-9
116. Lockey Sr SD. Hypersensitivity to tartrazine (FD&C Yellow No. 5) and other dyes and additives present in foods and pharmaceutical products. Ann Allergy 1977;38:206-10
117. Parodi G, Parodi A, Rebora A. Purpuric vasculitis due to tartrazine. Dermatologica 1985;171:623
118. Criep LH. Allergic vascular purpura. J Allergy 1971;48:7-12
119. Bell RT, Fishman S. Eosinophilia from food dye added to enteral feeding. N Engl J Med 1990;322:1822
120. Baungardner DJ. Persistent urticaria caused by a common coloring agent. Postgrad Med 1989;85:265-6
121. Pohl R, Balon R, Berchou R, et al. Allergy to tartrazine in antidepressants. Am J Psychiatry 1987;144:237-8
122. Stevenson DD, Simon RA, Lumry WR, et al. Adverse reactions to tartrazine. J Allergy Clin Immunol 1986;78:182-91
123. Morales MC, Basomba A, Pelaez A, et al. Challenge tests with tartrazine in patients with asthma associated with intolerance to analgesics (ASA-triad): a comparative study with placebo. Clin Allergy 1985;15:55-9
124. Hariparsad D, Wilson N, Dixon C, et al. Oral tartrazine challenge in childhood asthma: effect on bronchial reactivity. Clin Allergy 1984;14:81-5
125. Settipane GA. Adverse reactions of aspirin and related drugs. Arch Intern Med 1981;141:328-32
126. Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 1979;64:500-6
127. Juhlin L, Michaelsson G, Zetterstrom O. Urticaria and asthma induced by food-and-drug additives in patients with aspirin hypersensitivity. J Allergy Clin Immunol 1972;50:92-8
128. McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behavior in 3-year-old and 8/9-year-old children in the community: a randomized, double-blinded, placebo-controlled trial. Lancet 2007;370:1560-7
129. Rowe KS, Rowe KJ. Synthetic food coloring and behavior: a dose response effect in a double-blind, placebo-controlled, repeated-measures study. J Pediatr 1994;125:691-8
130. Thorley G. Pilot study to assess behavioural and cognitive effects of artificial food colours in a group of retarded children. Dev Med Child Neurol 1984;26:56-61
131. Adams W. Lack of behavioral effects from Feingold diet violations. Percept Mot Skills 1981;52:307-13
132. Mattes JA, Gittleman R. Effects of artificial food colorings in children with hyperactive symptoms: a critical review and results of a controlled study. Arch Gen Psychiatry 1981;38:714-18
133. Hastings G, Hughes K, Lowry R. Promoting sugar-free medicines: parents' view. Br J Gen Pract 1997;47:823-4
134. Hunter ML, Lewis R, Hunter B. Consumer demand in the purchase and prescription of sugar-free medicines. Int J Paediatr Dent 2000;10:140-4
135. Bentley EM, Mackie IC. A qualitative investigation into general medical practitioners' prescribing habits prior to a dental health education campaign. Health Education Research 1993;8:519-24
136. Bradley M, Kinirons MJ. Provision of sugar-free medicines for young children: the views of a sample of parents in Northern Ireland. J Ir Dent Assoc 1998;44:70-3
137. McVeigh N, Kinirons MJ. Pharmacists' knowledge, attitudes and practices concerning sugar-free medicines. Int J Paediatr Dent 1999;9:31-5